• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Was This Acquisition a Smart Move for GlaxoSmithKline?

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 15, 2022 at 11:12: PM
via
  • Momelotinib could be a potent treatment for bone marrow cancer patients.
  • The drug candidate could also become a blockbuster for GlaxoSmithKline.
  • Shares of the drugmaker seems like a good long-term buy for investors.

article source
 




Top Bottom
Back
Quote